Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Free Cash Flow (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Free Cash Flow for 7 consecutive years, with -$79.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 38.53% to -$79.7 million in Q4 2025 year-over-year; TTM through Nov 2025 was -$263.5 million, a 44.88% decrease, with the full-year FY2025 number at -$263.5 million, down 44.88% from a year prior.
  • Free Cash Flow was -$79.7 million for Q4 2025 at Nurix Therapeutics, down from -$53.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $31.9 million in Q4 2023 to a low of -$79.7 million in Q4 2025.
  • A 5-year average of -$38.9 million and a median of -$43.2 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 739.42% in 2022, then soared 207.5% in 2023.
  • Nurix Therapeutics' Free Cash Flow stood at -$31.8 million in 2021, then rose by 6.68% to -$29.6 million in 2022, then skyrocketed by 207.5% to $31.9 million in 2023, then tumbled by 280.53% to -$57.5 million in 2024, then plummeted by 38.53% to -$79.7 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Free Cash Flow are -$79.7 million (Q4 2025), -$53.3 million (Q3 2025), and -$65.8 million (Q2 2025).